INTRODUCTION: Theory of visual attention (TVA; Bundesen 1990) whole report tasks allow the independent measurement of visual perceptual processing speed and visual short-term memory (vSTM) storage capacity, unconfounded by motor speed. This study investigates how cognitive enhancing effects of psychostimulants depend on baseline performance and individual plasma levels. MATERIALS AND METHODS:Eighteen healthy volunteers (aged 20-35 years) received single oral doses of either 40 mg methylphenidate, 400 mg modafinil or placebo in a counterbalanced, double-blind crossover design. A whole report of visually presented letter arrays was performed 2.5-3.5 h after drug administration, and blood samples for plasma level analysis were taken. RESULTS:Methylphenidate and modafinil both enhanced perceptual processing speed in participants with low baseline (placebo) performance. These improvements correlated with subjective alertness. Furthermore, we observed differential plasma level-dependent effects of methylphenidate in lower and higher performing participants: higher plasma levels led to a greater improvement in low-performing participants and to decreasing improvement in high-performing participants. Modafinil enhanced visual short-term memory storage capacity in low-performing participants. CONCLUSIONS: This is the first pharmacological investigation demonstrating the usefulness of a TVA task for high-resolution and repeated cognitive parameter estimation after cognitive-enhancing medication. Our results confirm previous findings of attentional capacity improvements in low performers and extend the baseline dependency model to methylphenidate. Plasma level-dependent effects of psychostimulants can be modelled on an inverted U-shaped dose-response relationship, which is highly relevant to predict cognitive enhancing and detrimental effects of psychostimulants in patients with cognitive deficits (e.g., attention deficit hyperactivity disorder) and healthy volunteers (e.g., self-medicating academics).
RCT Entities:
INTRODUCTION: Theory of visual attention (TVA; Bundesen 1990) whole report tasks allow the independent measurement of visual perceptual processing speed and visual short-term memory (vSTM) storage capacity, unconfounded by motor speed. This study investigates how cognitive enhancing effects of psychostimulants depend on baseline performance and individual plasma levels. MATERIALS AND METHODS: Eighteen healthy volunteers (aged 20-35 years) received single oral doses of either 40 mg methylphenidate, 400 mg modafinil or placebo in a counterbalanced, double-blind crossover design. A whole report of visually presented letter arrays was performed 2.5-3.5 h after drug administration, and blood samples for plasma level analysis were taken. RESULTS:Methylphenidate and modafinil both enhanced perceptual processing speed in participants with low baseline (placebo) performance. These improvements correlated with subjective alertness. Furthermore, we observed differential plasma level-dependent effects of methylphenidate in lower and higher performing participants: higher plasma levels led to a greater improvement in low-performing participants and to decreasing improvement in high-performing participants. Modafinil enhanced visual short-term memory storage capacity in low-performing participants. CONCLUSIONS: This is the first pharmacological investigation demonstrating the usefulness of a TVA task for high-resolution and repeated cognitive parameter estimation after cognitive-enhancing medication. Our results confirm previous findings of attentional capacity improvements in low performers and extend the baseline dependency model to methylphenidate. Plasma level-dependent effects of psychostimulants can be modelled on an inverted U-shaped dose-response relationship, which is highly relevant to predict cognitive enhancing and detrimental effects of psychostimulants in patients with cognitive deficits (e.g., attention deficit hyperactivity disorder) and healthy volunteers (e.g., self-medicating academics).
Authors: Kathrin Finke; Peter Bublak; Joseph Krummenacher; Søren Kyllingsbaek; Hermann J Muller; Werner X Schneider Journal: J Int Neuropsychol Soc Date: 2005-11 Impact factor: 2.892
Authors: Ellen Matthias; Peter Bublak; Hermann J Müller; Werner X Schneider; Joseph Krummenacher; Kathrin Finke Journal: J Exp Psychol Hum Percept Perform Date: 2010-02 Impact factor: 3.332
Authors: Nicholas J Cooper; Hannah Keage; Daniel Hermens; Leanne M Williams; David Debrota; C Richard Clark; Evian Gordon Journal: J Integr Neurosci Date: 2005-03 Impact factor: 2.117
Authors: Samuel R Chamberlain; Jon E Grant; Anna Costa; Ulrich Müller; Barbara J Sahakian Journal: Psychopharmacology (Berl) Date: 2010-08-17 Impact factor: 4.530
Authors: Dara G Ghahremani; Golnaz Tabibnia; John Monterosso; Gerhard Hellemann; Russell A Poldrack; Edythe D London Journal: Neuropsychopharmacology Date: 2011-02-02 Impact factor: 7.853
Authors: Courtney A Marshall; Zachary D Brodnik; Ole V Mortensen; Maarten E A Reith; Jed S Shumsky; Barry D Waterhouse; Rodrigo A España; Sandhya Kortagere Journal: Neuropharmacology Date: 2019-01-08 Impact factor: 5.250
Authors: C M Fitzpatrick; M Caballero-Puntiverio; U Gether; T Habekost; C Bundesen; S Vangkilde; D P D Woldbye; J T Andreasen; A Petersen Journal: Psychopharmacology (Berl) Date: 2017-01-09 Impact factor: 4.530
Authors: Marieke E van der Schaaf; Sean J Fallon; Niels Ter Huurne; Jan Buitelaar; Roshan Cools Journal: Neuropsychopharmacology Date: 2013-04-23 Impact factor: 7.853